Cenobamate in pediatric Dravet syndrome: two responder cases challenging conventional sodium-channel blocker mechanisms

Two pediatric cases of Dravet syndrome (caused by SCN1A mutations) showed substantial seizure reduction with cenobamate despite the drug's sodium-channel blocking properties, which typically worsen this condition. The findings suggest cenobamate's mechanism may differ from classical sodium-channel blockers and warrant controlled trials to assess efficacy and safety in pediatric populations.